Literature DB >> 17086021

Endothelial vascular function in hypertensive patients after renin-angiotensin system blockade.

Leoní Adriana Souza-Barbosa1, Sílvia E Ferreira-Melo, Samira Ubaid-Girioli, Eduardo Arantes Nogueira, Juan Carlos Yugar-Toledo, Heitor Moreno.   

Abstract

It is unclear whether single and combined pharmacologic inhibition of the renin-angiotensin-aldosterone system have similar effects on endothelial function and blood pressure (BP). The authors evaluated 63 hypertensive patients divided into 4 groups (hydrochlorothiazide 25 mg/d; irbesartan [IRBE] 150 mg/d; quinapril [QUIN] 20 mg/d; or IRBE 150 mg/d + QUIN 20 mg/d) and 25 healthy normotensive subjects (normal) followed for 12 weeks. Endothelium-dependent dysfunction measured as flow-mediated dilation at Weeks 0 and 12 were: normal, 11.5%+/-2.4% vs 13.5%+/-2.0%; hydrochlorothiazide, 7.3%+/-2.0% vs 12.8%+/-3.1%; QUIN, 7.2%+/-2.8% vs 13.2%+/-2.1%; IRBE, 7.1%+/-2.8% vs 13.0%+/-2.9%; and IRBE + QUIN, 7.5%+/-1.9% vs 12.8%+/-3.0%. Nitroglycerin-mediated responses were: normal, 26.0%+/-1.9% vs 24.0%+/-2.5%; hydrochlorothiazide, 17.0%+/-2.2% vs 18.3%+/-2.6%; QUIN, 17.8%+/-3.2% vs 23.4%+/-3.0%; IRBE, 16.8%+/-3.6% vs 24.7%+/-2.0%; and IRBE + QUIN, 17.3%+/-3.0% vs 25.1%+/-2.5%. Antihypertensive therapy restored BP to normal and improved the endothelium-dependent and -independent dysfunction after renin-angiotensin-aldosterone system blockade. In a further finding, the combined effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade was not superior to the action of either of these treatments separately.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17086021

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  7 in total

Review 1.  Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information.

Authors:  Benjamin J Powers; Remy R Coeytaux; Rowena J Dolor; Vic Hasselblad; Uptal D Patel; William S Yancy; Rebecca N Gray; R Julian Irvine; Amy S Kendrick; Gillian D Sanders
Journal:  J Gen Intern Med       Date:  2011-12-07       Impact factor: 5.128

2.  The Global Burden of Cardiovascular Disease: The Role of Endothelial Function and Arterial Elasticity in Cardiovascular Disease as Novel and Emerging Biomarkers.

Authors:  Stephen P Glasser; Tanja Dudenbostel
Journal:  Curr Cardiovasc Risk Rep       Date:  2011-04-01

3.  The effect of antihypertensive drugs on endothelial function as assessed by flow-mediated vasodilation in hypertensive patients.

Authors:  Michiaki Miyamoto; Kazuhiko Kotani; Shun Ishibashi; Nobuyuki Taniguchi
Journal:  Int J Vasc Med       Date:  2012-02-29

Review 4.  Comparative Efficacy of Antihypertensive Agents in Flow-Mediated Vasodilation of Patients with Hypertension: Network Meta-Analysis of Randomized Controlled Trial.

Authors:  Hong Ding; Shu Liu; Ke-Xin Zhao; Jie Pu; Ya-Fei Xie; Xiao-Wei Zhang
Journal:  Int J Hypertens       Date:  2022-04-30       Impact factor: 2.434

5.  The effect of direct renin inhibition alone and in combination with ACE inhibition on endothelial function, arterial stiffness, and renal function in type 1 diabetes.

Authors:  David Z I Cherney; James W Scholey; Shan Jiang; Ronnie Har; Vesta Lai; Etienne B Sochett; Heather N Reich
Journal:  Diabetes Care       Date:  2012-07-26       Impact factor: 19.112

6.  Angiotensin II receptor blockers improve peripheral endothelial function: a meta-analysis of randomized controlled trials.

Authors:  Shuang Li; Yan Wu; Ge Yu; Qing Xia; Yawei Xu
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

Review 7.  Angiotensin receptor blockers & endothelial dysfunction: Possible correlation & therapeutic implications.

Authors:  Miroslav Radenkovic; Marko Stojanović; Ivana Milićević Nešić; Milica Prostran
Journal:  Indian J Med Res       Date:  2016-08       Impact factor: 2.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.